Ozempic vulva: Causes, prevention, and treatment

Rapid weight loss caused by Ozempic and other GLP-1 medications may cause fat loss from the vulva and vagina. This can change the appearance and comfort of the genital area.

While Ozempic and other GLP-1 receptor agonists are very effective for weight loss, they can cause various side effects, ranging from nausea and stomach issues to more surprising changes in physical appearance.

There are reports on social media of “Ozempic face,” which refers to the sagging or wrinkled skin that can occur when someone loses weight very quickly. Similarly, “Ozempic vulva” or Ozempic vagina” refer to changes in the appearance and feel of the vulva (the external part of the female genitals) and vagina (the internal part).

Ozempic vulva is not a medical diagnosis, and research has not reported specific effects on the female genitals. It is likely due to rapid weight loss, other factors, or a combination.

If a person is experiencing hormonal changes associated with perimenopause and menopause, they may also experience:

The primary cause of a saggy vulva after using a GLP-1 is rapid fat loss. The vulva consists of the labia majora (the outer folds of skin) and the labia minora (the inner folds).

The labia majora contains fat tissue that gives the area a plump, full appearance. When a person loses weight quickly, the body uses up fat stores, including those in the genital region.

If fat loss occurs rapidly, the skin’s elasticity and connective tissues may not adapt at the same pace, so skin can become loose and saggy.

While GLP-1s do not directly target the vulva, rapid weight loss makes these physical changes more noticeable than they would be a person lost weight slowly over several years. The same effect can occur anywhere on the body, including the face and breasts.

While weight loss is a major factor, there may be other reasons for changes in the vulva and vagina. Hormonal changes, particularly a drop in estrogen, can play a major role in the health of these tissues.

Estrogen is responsible for keeping the vaginal walls thick, elastic, and well-lubricated. When estrogen levels drop, which happens naturally during menopause or perimenopause, the tissues can become thin, dry, and fragile. This condition is known as atrophic vaginitis or genitourinary syndrome of menopause (GSM).

If a person is losing weight using a GLP-1 while also going through menopause, these two factors can combine. The weight loss removes the fatty padding of the vulva, while the lack of estrogen thins the skin and reduces moisture, leading to changes in both appearance and comfort.

In addition, aging naturally slows down metabolism and leads to a loss of muscle mass, which can further contribute to skin sagging across the entire body.

Preventing vulvovaginal changes mostly involves managing the pace of weight loss and maintaining overall skin health.

While it can be tempting to drop pounds as fast as possible, losing weight slowly, about one pound per week, may be better for your skin’s elasticity. This gives the skin more time to adapt, making sagging and loose skin less obvious.

If a person is experiencing vulvovaginal changes, the following medical and self-care treatments are available to help restore comfort and improve appearance:

Ozempic and other GLP-1 medications can affect the vulva and vagina primarily through rapid weight loss, which causes the protective fat tissue in the labia majora to disappear and the skin to sag.

Other factors, such as menopause and aging, can worsen these changes by thinning the skin and causing dryness.

Losing weight gradually can help prevent these issues, and treatments such as topical estrogen, moisturizers, and laser therapy are available to help restore the health of the area.